CL2012000263A1 - Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. - Google Patents

Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.

Info

Publication number
CL2012000263A1
CL2012000263A1 CL2012000263A CL2012000263A CL2012000263A1 CL 2012000263 A1 CL2012000263 A1 CL 2012000263A1 CL 2012000263 A CL2012000263 A CL 2012000263A CL 2012000263 A CL2012000263 A CL 2012000263A CL 2012000263 A1 CL2012000263 A1 CL 2012000263A1
Authority
CL
Chile
Prior art keywords
copd
useful
treatment
inflammatory diseases
compounds derived
Prior art date
Application number
CL2012000263A
Other languages
English (en)
Inventor
Lilian Alcaraz
Andrew Bailey
Nicholas Kindon
Original Assignee
Astrazeneca Ab
Pulmagen Therapeutics Synergy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41129405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Pulmagen Therapeutics Synergy filed Critical Astrazeneca Ab
Publication of CL2012000263A1 publication Critical patent/CL2012000263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un compuesto o una sal farmacéiuticamente aceptable del mismo.
CL2012000263A 2009-07-31 2012-01-31 Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. CL2012000263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0913342.2A GB0913342D0 (en) 2009-07-31 2009-07-31 Compounds - 801

Publications (1)

Publication Number Publication Date
CL2012000263A1 true CL2012000263A1 (es) 2012-08-31

Family

ID=41129405

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000263A CL2012000263A1 (es) 2009-07-31 2012-01-31 Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.

Country Status (33)

Country Link
US (2) US8455483B2 (es)
EP (1) EP2459572B1 (es)
JP (1) JP5612092B2 (es)
KR (1) KR101664525B1 (es)
CN (1) CN102625808B (es)
AR (1) AR080601A1 (es)
AU (1) AU2010277384B2 (es)
BR (1) BR112012008043A2 (es)
CA (1) CA2768527C (es)
CL (1) CL2012000263A1 (es)
CO (1) CO6491034A2 (es)
CR (1) CR20120054A (es)
CU (1) CU24103B1 (es)
DO (1) DOP2012000032A (es)
EA (1) EA020566B1 (es)
ES (1) ES2702467T3 (es)
GB (1) GB0913342D0 (es)
GT (1) GT201200028A (es)
HN (1) HN2012000217A (es)
IL (1) IL217557A (es)
MX (1) MX2012001232A (es)
MY (1) MY163117A (es)
NI (1) NI201200018A (es)
NZ (1) NZ597589A (es)
PE (1) PE20121441A1 (es)
SA (1) SA110310628B1 (es)
SG (1) SG177634A1 (es)
TR (1) TR201819140T4 (es)
TW (1) TWI443103B (es)
UA (1) UA106887C2 (es)
UY (1) UY32814A (es)
WO (1) WO2011012896A2 (es)
ZA (1) ZA201201473B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101273200B1 (ko) 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
GB201021992D0 (en) * 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) * 2010-12-23 2011-02-02 Astrazeneca Ab New compound
WO2016179349A1 (en) * 2015-05-05 2016-11-10 Northwestern University Cxcr4 chemokine receptor modulators
WO2018059537A1 (zh) * 2016-09-30 2018-04-05 四川海思科制药有限公司 一种二氮杂螺[5.5]十一碳烷衍生物及其用途
JP6963616B2 (ja) 2016-12-14 2021-11-10 ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド ４級アンモニウム塩構造を有する二官能性化合物
CN110678463B (zh) 2017-06-01 2023-06-06 百时美施贵宝公司 经取代的含氮化合物
EP3682906A1 (en) * 2019-01-17 2020-07-22 Julius-Maximilians-Universität Würzburg Compound targeting norepinephrine transporter

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707186A (en) 1954-05-06 1955-04-26 Hoffmann La Roche Imidazolone derivatives
AU565621B2 (en) 1983-04-26 1987-09-24 Smithkline Beckman Corporation Dopaminergic carbostyrils
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9604578D0 (en) 1996-03-04 1996-05-01 Sericol Ltd Photocurable compositions
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
JP4846709B2 (ja) 2004-03-10 2011-12-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５員複素環で置換されているｍｔｐ阻害性アリールピペリジン若しくはピペラジン
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
US20050215542A1 (en) 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
JP2008516939A (ja) 2004-10-15 2008-05-22 アストラゼネカ アクチボラグ 化学化合物
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
EP1961744B1 (en) * 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
AU2007284548A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
US20100056508A1 (en) * 2006-12-20 2010-03-04 Astrazeneca Ab Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases
GB0702413D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
KR101273200B1 (ko) * 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801

Also Published As

Publication number Publication date
AR080601A1 (es) 2012-04-25
CU20120021A7 (es) 2012-06-21
MY163117A (en) 2017-08-15
NI201200018A (es) 2012-09-10
ZA201201473B (en) 2012-11-28
EP2459572B1 (en) 2018-09-12
JP2013500958A (ja) 2013-01-10
EA201290077A1 (ru) 2012-08-30
WO2011012896A2 (en) 2011-02-03
EA020566B1 (ru) 2014-12-30
EP2459572A2 (en) 2012-06-06
TWI443103B (zh) 2014-07-01
CO6491034A2 (es) 2012-07-31
US20110053909A1 (en) 2011-03-03
TW201107335A (en) 2011-03-01
UY32814A (es) 2011-02-28
US20130018037A1 (en) 2013-01-17
HN2012000217A (es) 2015-03-09
TR201819140T4 (tr) 2019-01-21
ES2702467T3 (es) 2019-03-01
GB0913342D0 (en) 2009-09-16
KR20120056838A (ko) 2012-06-04
WO2011012896A3 (en) 2011-04-21
MX2012001232A (es) 2012-03-26
CA2768527C (en) 2017-07-11
NZ597589A (en) 2013-12-20
SA110310628B1 (ar) 2014-02-27
BR112012008043A2 (pt) 2020-08-25
JP5612092B2 (ja) 2014-10-22
GT201200028A (es) 2013-09-26
AU2010277384B2 (en) 2014-01-30
CN102625808B (zh) 2014-08-27
KR101664525B1 (ko) 2016-10-11
PE20121441A1 (es) 2012-11-16
CA2768527A1 (en) 2011-02-03
DOP2012000032A (es) 2017-08-15
US8455483B2 (en) 2013-06-04
UA106887C2 (uk) 2014-10-27
IL217557A0 (en) 2012-02-29
CR20120054A (es) 2012-03-26
US8476265B2 (en) 2013-07-02
SG177634A1 (en) 2012-02-28
CN102625808A (zh) 2012-08-01
CU24103B1 (es) 2015-07-30
IL217557A (en) 2015-01-29
HK1171755A1 (en) 2013-04-05
AU2010277384A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
ES2659758T3 (es) Antagonistas de receptores de 5-HT3
IL286793A (en) Midbrain dopamine (da) neurons for engraftment
MX2016006336A (es) Compuestos pirazolopirimidina.
JP2011168603A5 (es)
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
CL2015001231A1 (es) Compuestos heterocíclicos sustituidos con amida; composicion farmaceutica; útiles en el tratamiento de una enfermedad inflamatoria o autoinmune.
CR20110343A (es) Inhibidores de proteína cinasa
CO6501183A2 (es) Piperidinas sustituidas como antagonistas de ccr3
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
EP2726803A4 (en) INJECTION LACES WITH DIPPED PEAKS
EP2874626A4 (en) TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
EP2656872A4 (en) ELECTRODE PAD FOR IONTOPHORESIS
EA201370149A1 (ru) Антагонисты рецептора
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
UY35211A (es) Compuestos tricíclicos
GT201300241A (es) Composicion farmaceutica antihipertensiva
CO6870038A2 (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CO6801765A2 (es) Isoxazolinas como agentes terapéuticos
UY35209A (es) Compuestos tricíclicos
EP2874622A4 (en) TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
EP2821073A4 (en) MEDIUM TO IMPROVE BIORHYTHMUS
EP2754653A4 (en) AZETIDINE DERIVATIVE AND ANTIDEPRESSIVE COMPOSITION THEREOF